Inscripta joins EuropaBio: delivering global biotechnology advances

Brussels, 6 April 2021 – EuropaBio is pleased to announce that United States-based Inscripta has joined as an associate member.

Inscripta, known as the ‘the digital genome engineering company,’ has developed the world’s first ‘benchtop biofoundry.’ The Onyx™ platform, which aims to bring genome technology breakthroughs into everyday lab use, is built on the company’s integrated CRISPR-based system which includes an instrument, consumables, software, and assays. Parallel genome engineering experiments in an automated and scalable workflow are all now accessible at the benchtop with the touch of a button.

Founded in 2015, Inscripta is now expanding its operations into Europe through a new office in Copenhagen, Denmark.

EuropaBio Director-General Dr. Claire Skentelbery says “Inscripta shows the pathway of how biotechnology is applied to accelerate R&D across all sectors. We are absolutely delighted to have the Inscripta team on board and will be working with them across our Councils for a competitive biotech sector.”

Inscripta CEO Sri Kosaraju added, “We are pleased to be joining EuropaBio and are looking forward to expanding our collaborations with the European genome engineering community. Inscripta’s goal is to empower scientists around the world with technologies that enable them to probe the genome with unprecedented breadth and speed. We believe that the Onyx platform will help usher in a new era of biological discovery and yield solutions that benefit all, such as sustainably derived materials, improved crops and better foods, and new and improved ways to treat disease.”

Download the full PRESS RELEASE below.